Topically Applied Phospho-Sulindac Hydrogel is Efficacious and Safe in the Treatment of Experimental Arthritis in Rats
详细信息 查看全文
- 作者：George Mattheolabakis (1)
Gerardo G. Mackenzie (1)
Liqun Huang (1)
Nengtai Ouyang (1)
Ka Wing Cheng (1)
Basil Rigas (1) (1) - 关键词：arthritis ; hydrogel ; NSAIDs ; phospho ; sulindac ; transdermal
- 刊名：Pharmaceutical Research
- 出版年：2013
- 出版时间：June 2013
- 年：2013
- 卷：30
- 期：6
- 页码：1471-1482
- 全文大小：637KB
- 参考文献：1. Alamanosand Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev. 2005;4:130鈥?. CrossRef
2. Eureniusand E, Stenstrom CH. Physical activity, physical fitness, and general health perception among individuals with rheumatoid arthritis. Arthritis Rheum. 2005;53:48鈥?5. CrossRef
3. Rahmeand E, Bernatsky S. NSAIDs and risk of lower gastrointestinal bleeding. Lancet. 2010;376:146鈥?. CrossRef
4. Sostres C, Gargallo CJ, Arroyo MT, Lanas A. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2010;24:121鈥?2. CrossRef
5. Farkouhand ME, Greenberg BP. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol. 2009;103:1227鈥?7. CrossRef
6. McGettiganand P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA J Am Med Assoc. 2006;296:1633鈥?4. CrossRef
7. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 2002;360:1071鈥?. CrossRef
8. Rainsford KD. Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs). Am J Med. 1999;107:27S鈥?5. discussion 35S鈥?6S. CrossRef
9. Huang L, Mackenzie G, Ouyang N, Sun Y, Xie G, Johnson F, / et al. The novel phospho-non-steroidal anti-inflammatory drugs, OXT-328, MDC-22 and MDC-917, inhibit adjuvant-induced arthritis in rats. Br J Pharmacol. 2011;162:1521鈥?3. CrossRef
10. Huang L, Zhu C, Sun Y, Xie G, Mackenzie GG, Qiao G, / et al. Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effect. Carcinogenesis. 2010;31:1982鈥?0. CrossRef
11. Mackenzie GG, Sun Y, Huang L, Xie G, Ouyang N, Gupta RC, / et al. Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice. Gastroenterology. 2010;139:1320鈥?2. CrossRef
12. Wong CC, Cheng KW, Xie G, Zhou D, Zhu CH, Constantinides PP, / et al. Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal anti-inflammatory drugs: relevance to their pharmacological activity. J Pharmacol Exp Ther. 2012;340:422鈥?2. CrossRef
13. Xie G, Nie T, Mackenzie GG, Sun Y, Huang L, Ouyang N, / et al. The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine. Br J Pharmacol. 2012;165:2152鈥?6. CrossRef
14. Kalia YN, Naik A, Garrison J, Guy RH. Iontophoretic drug delivery. Adv Drug Deliv Rev. 2004;56:619鈥?8. CrossRef
15. Naik A, Kalia YN, Guy RH. Transdermal drug delivery: overcoming the skin鈥檚 barrier function. Pharm Sci Technol Today. 2000;3:318鈥?6. CrossRef
16. Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov. 2004;3:115鈥?4. CrossRef
17. Rhee YS, Chang SY, Park CW, Chi SC, Park ES. Optimization of ibuprofen gel formulations using experimental design technique for enhanced transdermal penetration. Int J Pharm. 2008;364:14鈥?0. CrossRef
18. Farringtonand K, Regan F. Molecularly imprinted sol gel for ibuprofen: an analytical study of the factors influencing selectivity. Talanta. 2009;78:653鈥?. CrossRef
19. Ustundag Okur N, Apaydin S, Karabay Yavasoglu NU, Yavasoglu A, Karasulu HY. Evaluation of skin permeation and anti-inflammatory and analgesic effects of new naproxen microemulsion formulations. Int J Pharm. 2011;416:136鈥?4.
20. Huang ZJ, Hsu E, Li HC, Rosner AL, Rupert RL, Song XJ. Topical application of compound Ibuprofen suppresses pain by inhibiting sensory neuron hyperexcitability and neuroinflammation in a rat model of intervertebral foramen inflammation. J Pain Off J Am Pain Soc. 2011;12:141鈥?2. CrossRef
21. Taboada M, Santen R, Lima J, Hossain J, Singh R, Klein KO, / et al. Pharmacokinetics and pharmacodynamics of oral and transdermal 17beta estradiol in girls with Turner syndrome. J Clin Endocrinol Metab. 2011;96:3502鈥?0. CrossRef
22. Yerramsetty KM, Rachakonda VK, Neely BJ, Madihally SV, Gasem KA. Effect of different enhancers on the transdermal permeation of insulin analog. Int J Pharm. 2010;398:83鈥?2. CrossRef
23. Pillaiand O, Panchagnula R. Transdermal delivery of insulin from poloxamer gel: / ex vivo and / in vivo skin permeation studies in rat using iontophoresis and chemical enhancers. J Control Release Off J Control Release Soc. 2003;89:127鈥?0. CrossRef
24. Wan DH, Zheng O, Zhou Y, Wu LY. Solubilization of Ibuprofen in Pluronic Block Copolymer F127 Micelles. Acta Phys-Chim Sin. 2010;26:3243鈥?.
25. Foster B, Cosgrove T, Hammouda B. Pluronic triblock copolymer systems and their interactions with ibuprofen. Langmuir. 2009;25:6760鈥?. CrossRef
26. Wanka G, Hoffmann H, Ulbricht W. Phase-diagrams and aggregation behavior of poly(oxyethylene)-poly(oxypropylene)-poly(oxyethylene) triblock copolymers in aqueous-solutions. Macromolecules. 1994;27:4145鈥?9. CrossRef
27. Alexandridis P. Poly(ethylene oxide) poly(propylene oxide) block copolymer surfactants. Curr Opin Colloid Interface Sci. 1997;2:478鈥?9. CrossRef
28. Cabana A, AitKadi A, Juhasz J. Study of the gelation process of polyethylene oxide(a) polypropylene oxide(b) polyethylene oxide(a) copolymer (Poloxamer 407) aqueous solutions. J Colloid Interface Sci. 1997;190:307鈥?2. CrossRef
29. Anderson BC, Pandit NK, Mallapragada SK. Understanding drug release from poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide) gels. J Control Release Off J Control Release Soc. 2001;70:157鈥?7. CrossRef
30. Cheng KW, Mattheolabakis G, Wong CC, Ouyang N, Huang L, Constantinides PP, / et al. Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer. Int J Oncol. 2012;41:1199鈥?203.
31. Schmolka IR. Artificial skin. I. Preparation and properties of pluronic F-127 gels for treatment of burns. J Biomed Mater Res. 1972;6:571鈥?2. CrossRef
32. Whiteley PE, Dalrymple SA. Models of inflammation: adjuvant-induced arthritis in the rat. Curr Protoc Pharmacol. 2001;Chapter 5:Unit5 5.
33. Bendele A. Animal models of rheumatoid arthritis. J Musculoskelet Neuronal Interact. 2001;1:377鈥?5.
34. Bendele A, McComb J, Gould T, McAbee T, Sennello G, Chlipala E, / et al. Animal models of arthritis: relevance to human disease. Toxicol Pathol. 1999;27:134鈥?2. CrossRef
35. Ahnand KS, Aggarwal BB. Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann N Y Acad Sci. 2005;1056:218鈥?3. CrossRef
36. Mattheolabakis G, Lagoumintzis G, Panagi Z, Papadimitriou E, Partidos CD, Avgoustakis K. Transcutaneous delivery of a nanoencapsulated antigen: induction of immune responses. Int J Pharm. 2010;385:187鈥?3. CrossRef
37. Lioneand A, Scialli AR. The developmental toxicity of indomethacin and sulindac. Reprod Toxicol. 1995;9:7鈥?0. CrossRef
38. Roman-Blasand JA, Jimenez SA. NF-kappa B as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthr Cartil. 2006;14:839鈥?8. CrossRef
39. Anderson GD, Hauser SD, McGarity KL, Bremer ME, Isakson PC, Gregory SA. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest. 1996;97:2672鈥?. CrossRef - 作者单位：George Mattheolabakis (1)
Gerardo G. Mackenzie (1)
Liqun Huang (1)
Nengtai Ouyang (1)
Ka Wing Cheng (1)
Basil Rigas (1) (1)
1. Division of Cancer Prevention, Department of Medicine, Stony Brook University, HSC, T17-080, Stony Brook, New York, 11794-8173, USA - ISSN：1573-904X
文摘